Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Meets Expectations

Cytek Biosciences (NASDAQ:CTKB) released its quarterly earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09), FiscalAI reports. Cytek Biosciences had a negative net margin of 38.98% and a negative return on equity of 12.16%. The firm had revenue of $48.14 million during the quarter, compared to the consensus estimate of $47.31 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

• Q2 revenue increased 6% year over year to $48.1 million, driven by 18% growth in the U.S., strong double-digit growth in China, high-end FSP instrument sales, and continued service momentum. Management raised the low end of full-year 2026 revenue guidance to $207 million-$212 million.
• Recurring revenue continued to strengthen, with service revenue up 10% to $15.6 million and combined reagents and service revenue representing 35% of trailing-12-month revenue. Cytek expects adjusted EBITDA to improve in the second half and reach approximately breakeven for full-year 2026.
• Cytek launched the Borealis, a 60-color, seven-laser full spectral-flow cytometer, and expanded Aurora Evo automation capabilities for biopharma and CRO laboratories. Management said early customer feedback on Borealis has been strong and believes the products can support future market-share gains.
• Regional and profitability pressures persisted: EMEA revenue declined approximately 8% amid government budget constraints, while GAAP net loss widened to $12.2 million from $5.6 million a year earlier. Operating expenses rose 15%, including higher legal costs tied to patent litigation and increased personnel expenses.
• The company began reorganizing into three customer-aligned business units—Solutions and Clinical, Research Technology, and Service—aiming to improve market penetration and growth, particularly in mid- and low-end instruments, reagents, and clinical applications. Management said the benefits will take time to materialize and are already incorporated into 2026 guidance.

Cytek Biosciences Price Performance

Shares of NASDAQ CTKB traded up $0.01 during trading hours on Friday, hitting $4.17. 132,815 shares of the company’s stock were exchanged, compared to its average volume of 1,023,926. The company’s 50-day moving average price is $4.32 and its 200-day moving average price is $4.41. The stock has a market capitalization of $539.03 million, a price-to-earnings ratio of -6.65 and a beta of 1.17. Cytek Biosciences has a 1-year low of $3.28 and a 1-year high of $6.18.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Stephens decreased their price objective on shares of Cytek Biosciences from $5.50 to $4.75 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytek Biosciences in a report on Wednesday, June 24th. Finally, Morgan Stanley set a $5.00 price objective on shares of Cytek Biosciences in a research report on Friday. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $5.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CTKB. Federated Hermes Inc. increased its holdings in shares of Cytek Biosciences by 150.9% during the second quarter. Federated Hermes Inc. now owns 7,221 shares of the company’s stock worth $25,000 after buying an additional 4,343 shares in the last quarter. Captrust Financial Advisors acquired a new stake in Cytek Biosciences during the 2nd quarter valued at $43,000. CIBC Bancorp USA Inc. acquired a new position in Cytek Biosciences in the third quarter worth $43,000. Tower Research Capital LLC TRC boosted its stake in Cytek Biosciences by 338.1% in the second quarter. Tower Research Capital LLC TRC now owns 19,760 shares of the company’s stock worth $67,000 after purchasing an additional 15,250 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Cytek Biosciences during the third quarter worth $75,000. 69.46% of the stock is owned by institutional investors.

Cytek Biosciences Company Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.